Increasing Prevalence of HIV Pretreatment Drug Resistance in Women but Not Men in Rural Uganda during 2005-2013

Suzanne M. McCluskey, Guinevere Q. Lee, Kimia Kamelian, Annet Kembabazi, Nicholas Musinguzi, Mwebesa B. Bwana, Conrad Muzoora, Jessica E. Haberer, Peter W. Hunt, Jeffrey N. Martin, Yap Boum, David Bangsberg, P. Richard Harrigan, Mark J. Siedner

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The prevalence of HIV pretreatment drug resistance (PDR) is increasing in sub-Saharan Africa. We sought to describe correlates of PDR and evaluate effects of PDR on clinical outcomes in rural Uganda. We analyzed data from the Uganda AIDS Rural Treatment Outcomes study, a cohort of antiretroviral therapy (ART)-naive adults with HIV (2005-2015). We performed resistance testing on pre-ART specimens. We defined PDR as any World Health Organization (WHO) 2009 surveillance drug resistance mutation and classified PDR level using the Stanford algorithm. We fit unadjusted and sex-stratified log binomial regression and Cox proportional hazard models to identify correlates of PDR and the impact of PDR on viral suppression, loss to follow-up (LTFU), and death. We analyzed data from 738 participants (median age 33 years, 69% female). Overall, prevalence of PDR was 3.5% (n = 26), owing mostly to resistance to non-nucleoside reverse transcriptase inhibitors. PDR increased over time in women (1.8% in those enrolling in clinic in 2001-2006, vs. 7.0% in 2007-2013; p = 0.006), but not in men (1.15% vs. 0.72%, p = 0.737). Lower pre-ART log10 HIV RNA was also associated with higher prevalence of PDR. We identified longer time to viral suppression among those with PDR compared with without PDR (0.5 and 0.3 years, respectively, p = 0.023), but there was no significant relationship with mortality or LTFU (p = 0.139). We observed increasing rates of PDR in women in southwestern Uganda. Implications of this trend, particularly to prevention of mother-to-child transmission programs in the region, require attention due to delayed viral suppression among those with PDR.

Original languageEnglish (US)
Pages (from-to)257-264
Number of pages8
JournalAIDS Patient Care and STDs
Volume32
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Uganda
Drug Resistance
HIV
Viral Drug Resistance
Reverse Transcriptase Inhibitors
Africa South of the Sahara
Proportional Hazards Models

Keywords

  • antiretroviral therapy
  • HIV-1
  • resistance
  • sub-Saharan Africa
  • viral suppression

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

McCluskey, S. M., Lee, G. Q., Kamelian, K., Kembabazi, A., Musinguzi, N., Bwana, M. B., ... Siedner, M. J. (2018). Increasing Prevalence of HIV Pretreatment Drug Resistance in Women but Not Men in Rural Uganda during 2005-2013. AIDS Patient Care and STDs, 32(7), 257-264. https://doi.org/10.1089/apc.2018.0020

Increasing Prevalence of HIV Pretreatment Drug Resistance in Women but Not Men in Rural Uganda during 2005-2013. / McCluskey, Suzanne M.; Lee, Guinevere Q.; Kamelian, Kimia; Kembabazi, Annet; Musinguzi, Nicholas; Bwana, Mwebesa B.; Muzoora, Conrad; Haberer, Jessica E.; Hunt, Peter W.; Martin, Jeffrey N.; Boum, Yap; Bangsberg, David; Harrigan, P. Richard; Siedner, Mark J.

In: AIDS Patient Care and STDs, Vol. 32, No. 7, 01.07.2018, p. 257-264.

Research output: Contribution to journalArticle

McCluskey, SM, Lee, GQ, Kamelian, K, Kembabazi, A, Musinguzi, N, Bwana, MB, Muzoora, C, Haberer, JE, Hunt, PW, Martin, JN, Boum, Y, Bangsberg, D, Harrigan, PR & Siedner, MJ 2018, 'Increasing Prevalence of HIV Pretreatment Drug Resistance in Women but Not Men in Rural Uganda during 2005-2013', AIDS Patient Care and STDs, vol. 32, no. 7, pp. 257-264. https://doi.org/10.1089/apc.2018.0020
McCluskey, Suzanne M. ; Lee, Guinevere Q. ; Kamelian, Kimia ; Kembabazi, Annet ; Musinguzi, Nicholas ; Bwana, Mwebesa B. ; Muzoora, Conrad ; Haberer, Jessica E. ; Hunt, Peter W. ; Martin, Jeffrey N. ; Boum, Yap ; Bangsberg, David ; Harrigan, P. Richard ; Siedner, Mark J. / Increasing Prevalence of HIV Pretreatment Drug Resistance in Women but Not Men in Rural Uganda during 2005-2013. In: AIDS Patient Care and STDs. 2018 ; Vol. 32, No. 7. pp. 257-264.
@article{11804154d8024ce9aa96889b4bcd6945,
title = "Increasing Prevalence of HIV Pretreatment Drug Resistance in Women but Not Men in Rural Uganda during 2005-2013",
abstract = "The prevalence of HIV pretreatment drug resistance (PDR) is increasing in sub-Saharan Africa. We sought to describe correlates of PDR and evaluate effects of PDR on clinical outcomes in rural Uganda. We analyzed data from the Uganda AIDS Rural Treatment Outcomes study, a cohort of antiretroviral therapy (ART)-naive adults with HIV (2005-2015). We performed resistance testing on pre-ART specimens. We defined PDR as any World Health Organization (WHO) 2009 surveillance drug resistance mutation and classified PDR level using the Stanford algorithm. We fit unadjusted and sex-stratified log binomial regression and Cox proportional hazard models to identify correlates of PDR and the impact of PDR on viral suppression, loss to follow-up (LTFU), and death. We analyzed data from 738 participants (median age 33 years, 69{\%} female). Overall, prevalence of PDR was 3.5{\%} (n = 26), owing mostly to resistance to non-nucleoside reverse transcriptase inhibitors. PDR increased over time in women (1.8{\%} in those enrolling in clinic in 2001-2006, vs. 7.0{\%} in 2007-2013; p = 0.006), but not in men (1.15{\%} vs. 0.72{\%}, p = 0.737). Lower pre-ART log10 HIV RNA was also associated with higher prevalence of PDR. We identified longer time to viral suppression among those with PDR compared with without PDR (0.5 and 0.3 years, respectively, p = 0.023), but there was no significant relationship with mortality or LTFU (p = 0.139). We observed increasing rates of PDR in women in southwestern Uganda. Implications of this trend, particularly to prevention of mother-to-child transmission programs in the region, require attention due to delayed viral suppression among those with PDR.",
keywords = "antiretroviral therapy, HIV-1, resistance, sub-Saharan Africa, viral suppression",
author = "McCluskey, {Suzanne M.} and Lee, {Guinevere Q.} and Kimia Kamelian and Annet Kembabazi and Nicholas Musinguzi and Bwana, {Mwebesa B.} and Conrad Muzoora and Haberer, {Jessica E.} and Hunt, {Peter W.} and Martin, {Jeffrey N.} and Yap Boum and David Bangsberg and Harrigan, {P. Richard} and Siedner, {Mark J.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1089/apc.2018.0020",
language = "English (US)",
volume = "32",
pages = "257--264",
journal = "AIDS Patient Care and STDs",
issn = "1087-2914",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - Increasing Prevalence of HIV Pretreatment Drug Resistance in Women but Not Men in Rural Uganda during 2005-2013

AU - McCluskey, Suzanne M.

AU - Lee, Guinevere Q.

AU - Kamelian, Kimia

AU - Kembabazi, Annet

AU - Musinguzi, Nicholas

AU - Bwana, Mwebesa B.

AU - Muzoora, Conrad

AU - Haberer, Jessica E.

AU - Hunt, Peter W.

AU - Martin, Jeffrey N.

AU - Boum, Yap

AU - Bangsberg, David

AU - Harrigan, P. Richard

AU - Siedner, Mark J.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The prevalence of HIV pretreatment drug resistance (PDR) is increasing in sub-Saharan Africa. We sought to describe correlates of PDR and evaluate effects of PDR on clinical outcomes in rural Uganda. We analyzed data from the Uganda AIDS Rural Treatment Outcomes study, a cohort of antiretroviral therapy (ART)-naive adults with HIV (2005-2015). We performed resistance testing on pre-ART specimens. We defined PDR as any World Health Organization (WHO) 2009 surveillance drug resistance mutation and classified PDR level using the Stanford algorithm. We fit unadjusted and sex-stratified log binomial regression and Cox proportional hazard models to identify correlates of PDR and the impact of PDR on viral suppression, loss to follow-up (LTFU), and death. We analyzed data from 738 participants (median age 33 years, 69% female). Overall, prevalence of PDR was 3.5% (n = 26), owing mostly to resistance to non-nucleoside reverse transcriptase inhibitors. PDR increased over time in women (1.8% in those enrolling in clinic in 2001-2006, vs. 7.0% in 2007-2013; p = 0.006), but not in men (1.15% vs. 0.72%, p = 0.737). Lower pre-ART log10 HIV RNA was also associated with higher prevalence of PDR. We identified longer time to viral suppression among those with PDR compared with without PDR (0.5 and 0.3 years, respectively, p = 0.023), but there was no significant relationship with mortality or LTFU (p = 0.139). We observed increasing rates of PDR in women in southwestern Uganda. Implications of this trend, particularly to prevention of mother-to-child transmission programs in the region, require attention due to delayed viral suppression among those with PDR.

AB - The prevalence of HIV pretreatment drug resistance (PDR) is increasing in sub-Saharan Africa. We sought to describe correlates of PDR and evaluate effects of PDR on clinical outcomes in rural Uganda. We analyzed data from the Uganda AIDS Rural Treatment Outcomes study, a cohort of antiretroviral therapy (ART)-naive adults with HIV (2005-2015). We performed resistance testing on pre-ART specimens. We defined PDR as any World Health Organization (WHO) 2009 surveillance drug resistance mutation and classified PDR level using the Stanford algorithm. We fit unadjusted and sex-stratified log binomial regression and Cox proportional hazard models to identify correlates of PDR and the impact of PDR on viral suppression, loss to follow-up (LTFU), and death. We analyzed data from 738 participants (median age 33 years, 69% female). Overall, prevalence of PDR was 3.5% (n = 26), owing mostly to resistance to non-nucleoside reverse transcriptase inhibitors. PDR increased over time in women (1.8% in those enrolling in clinic in 2001-2006, vs. 7.0% in 2007-2013; p = 0.006), but not in men (1.15% vs. 0.72%, p = 0.737). Lower pre-ART log10 HIV RNA was also associated with higher prevalence of PDR. We identified longer time to viral suppression among those with PDR compared with without PDR (0.5 and 0.3 years, respectively, p = 0.023), but there was no significant relationship with mortality or LTFU (p = 0.139). We observed increasing rates of PDR in women in southwestern Uganda. Implications of this trend, particularly to prevention of mother-to-child transmission programs in the region, require attention due to delayed viral suppression among those with PDR.

KW - antiretroviral therapy

KW - HIV-1

KW - resistance

KW - sub-Saharan Africa

KW - viral suppression

UR - http://www.scopus.com/inward/record.url?scp=85049797493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049797493&partnerID=8YFLogxK

U2 - 10.1089/apc.2018.0020

DO - 10.1089/apc.2018.0020

M3 - Article

VL - 32

SP - 257

EP - 264

JO - AIDS Patient Care and STDs

JF - AIDS Patient Care and STDs

SN - 1087-2914

IS - 7

ER -